ERBB2 and cancer: This explains why a relatively large fraction of the genes undergoing recurrent somatic mutations in cancer affect protein kinases and other signaling proteins placed downstream of RTKs [7], such as B-RAF (in melanoma), RAS (in pancreatic cancer) ERBB2/HER2 (in breast cancer), and EGFR (in brain cancer).